The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HNGE | N/A | N/A | N/A | +4% |
| S&P | +11.79% | +73.73% | +11.67% | +17% |
Hinge Health, Inc. engages in the development of technology platform for the treatment of musculoskeletal (MSK) conditions. Its platform addresses a broad spectrum of MSK care, from acute injury to chronic pain and to post-surgical rehabilitation. The company was founded by Daniel Perez and Gabriel Mecklenburg in 2014 and is headquartered in San Francisco, CA.
Think Hinge stock is a buy at less than 15x FCF? So do I.
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $170.73M | 45.6% |
| Gross Profit | $144.03M | 49.9% |
| Gross Margin | 84.36% | 2.4% |
| Market Cap | $3.66B | 0.0% |
| Net Income | $31.09M | 14.6% |
| EBITDA | $28.48M | 33.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $209.80M | -30.7% |
| Accounts Receivable | $66.06M | 55.5% |
| Inventory | 15.6 | -37.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.82M | -47.4% |
| Short Term Debt | $4.22M | 10.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -59.86% | -58.0% |
| Return On Invested Capital | -13.74% | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $61.53M | 0.0% |
| Operating Free Cash Flow | $63.89M | 0.0% |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | -13.10 | 22.07 | 17.58 | - | |
| Price to Sales | 8.41 | 7.23 | - | ||
| Price to Tangible Book Value | -10.75 | 35.93 | 25.90 | - | |
| Enterprise Value to EBITDA | -1049.65 | 126.14 | - | ||
| Return on Equity | -2.8% | -106.9% | - | ||
| Total Debt | $10.13M | $9.97M | $9.03M | $8.04M | -27.39% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
